Bank of Montreal Can acquired a new stake in BioDelivery Sciences International, Inc. (NASDAQ:BDSI) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 47,096 shares of the specialty pharmaceutical company’s stock, valued at approximately $138,000. Bank of Montreal Can owned about 0.08% of BioDelivery Sciences International at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in BDSI. venBio Select Advisor LLC grew its stake in shares of BioDelivery Sciences International by 120.2% in the 1st quarter. venBio Select Advisor LLC now owns 5,437,779 shares of the specialty pharmaceutical company’s stock valued at $12,235,000 after buying an additional 2,968,291 shares during the period. GSA Capital Partners LLP grew its stake in shares of BioDelivery Sciences International by 12.7% in the 1st quarter. GSA Capital Partners LLP now owns 460,567 shares of the specialty pharmaceutical company’s stock valued at $1,036,000 after buying an additional 51,900 shares during the period. Foresite Capital Management III LLC purchased a new stake in shares of BioDelivery Sciences International in the 1st quarter valued at approximately $338,000. Knott David M purchased a new stake in shares of BioDelivery Sciences International in the 1st quarter valued at approximately $270,000. Finally, Millennium Management LLC purchased a new stake in shares of BioDelivery Sciences International in the 4th quarter valued at approximately $310,000. Institutional investors own 45.50% of the company’s stock.

NASDAQ:BDSI opened at $2.85 on Friday. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.16 and a quick ratio of 2.90. The company has a market cap of $166.77 million, a P/E ratio of -7.31 and a beta of 0.38. BioDelivery Sciences International, Inc. has a fifty-two week low of $1.70 and a fifty-two week high of $3.20.

BioDelivery Sciences International (NASDAQ:BDSI) last posted its quarterly earnings data on Thursday, August 9th. The specialty pharmaceutical company reported ($0.16) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.18) by $0.02. The firm had revenue of $12.18 million during the quarter, compared to analysts’ expectations of $12.44 million. BioDelivery Sciences International had a negative net margin of 103.01% and a negative return on equity of 278.79%. equities analysts forecast that BioDelivery Sciences International, Inc. will post -0.62 EPS for the current year.

Several analysts have recently weighed in on the stock. Cantor Fitzgerald reissued a “buy” rating and issued a $4.50 price target on shares of BioDelivery Sciences International in a research note on Thursday, August 9th. Zacks Investment Research raised shares of BioDelivery Sciences International from a “hold” rating to a “buy” rating and set a $3.25 price target for the company in a research note on Monday, July 23rd. HC Wainwright dropped their price target on shares of BioDelivery Sciences International from $4.00 to $3.50 and set a “buy” rating for the company in a research note on Wednesday, May 23rd. ValuEngine raised shares of BioDelivery Sciences International from a “sell” rating to a “hold” rating in a research note on Friday, June 1st. Finally, Roth Capital set a $4.00 price target on shares of BioDelivery Sciences International and gave the company a “buy” rating in a research note on Friday, May 11th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $4.13.

BioDelivery Sciences International Profile

BioDelivery Sciences International, Inc, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies.

Featured Story: Outstanding Shares

Want to see what other hedge funds are holding BDSI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioDelivery Sciences International, Inc. (NASDAQ:BDSI).

Institutional Ownership by Quarter for BioDelivery Sciences International (NASDAQ:BDSI)

Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.